Premium
Randomized, Double‐Blind, Single‐Dose, Placebo‐Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects
Author(s) -
Mendell Jeanne,
Kobayashi Fumiaki,
Shimizu Takako
Publication year - 2020
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.794
Subject(s) - medicine , qt interval , moxifloxacin , placebo , crossover study , confidence interval , proarrhythmia , anesthesia , adverse effect , repolarization , assay sensitivity , pharmacokinetics , pharmacology , cardiology , antibiotics , electrophysiology , alternative medicine , pathology , microbiology and biotechnology , biology
This phase 1 single‐center, single‐dose, double‐dummy, placebo‐controlled, 4‐period and 4‐sequence crossover study assessed the potential of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker used to treat hypertension, to affect cardiac repolarization. In this double‐blind study, 55 subjects were randomized to single doses of 10 mg esaxerenone (therapeutic dose), 40 mg esaxerenone (supratherapeutic dose), 400 mg moxifloxacin, or placebo. Serial electrocardiograms and pharmacokinetics (PK) were obtained over 24 and 168 hours, respectively. The primary end point was Fridericia‐corrected QT interval (QTcF). Secondary end points included safety and PK. Assay sensitivity was confirmed as the lower limit of 90% confidence interval (90%CIs) for placebo‐corrected change from baseline QTcF (∆∆QTcF) for moxifloxacin was >5 milliseconds at the prespecified times; mean ∆∆QTcF was 12.5 milliseconds at 3 and 4 hours postdose. The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone. No concentration‐QTc relationship was identified. Therefore, esaxerenone had no potential to inhibit cardiac repolarization. No deaths or serious adverse events (AEs) occurred; 1 subject discontinued the study because of a treatment‐emergent AE unrelated to esaxerenone. This clinical evaluation showed that esaxerenone has no QTc prolongation potential.